FCM
VKTX icon

Frontier Capital Management’s Viking Therapeutics VKTX Stock Holding History

Frontier Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-638,204
Closed -$16.9M – 317
2025
Q2 		$16.9M Buy
638,204
+220,396
+53% +$5.8M 0.16% 201
2025
Q1 		$10.1M Sell
417,808
-179,931
-30% -$5.69M 0.11% 218
2024
Q4 		$24.1M Buy
597,739
+16,321
+3% +$931K 0.23% 159
2024
Q3 		$36.8M Buy
581,418
+131,221
+29% +$7.7M 0.35% 112
2024
Q2 		$23.9M Buy
450,197
+284,788
+172% +$18.7M 0.24% 155
2024
Q1 		$13.6M Buy
+165,409
New +$7.36M 0.13% 199

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Frontier Capital Management's VKTX Position: Q3 2025 in Review

Frontier Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 638,204 shares — an estimated $16.9M sold.

Frontier Capital Management first reported a position in VKTX in Q1 2024 and held it in 6 quarters. The position peaked at $36.8M in Q3 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Frontier Capital Management reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Frontier Capital Management sold 638,204 Viking Therapeutics shares in Q3 2025, an estimated $16.9M.
  • Frontier Capital Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 6 quarters.
  • Frontier Capital Management's Viking Therapeutics position peaked at $36.8M in Q3 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Frontier Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.